Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute Coronavirus Disease 2019 in Pediatric Patients | Zendy

Daniel E. Dulek | Zendy; Robert C. Fuhlbrigge | Zendy; Alison C. Tribble | Zendy; James A. Connelly | Zendy; Michele Loi | Zendy; Hassan El Chebib | Zendy; Shanmuganathan Chandrakasan | Zendy; W Otto | Zendy; Caroline Diorio | Zendy; Garrett Keim | Zendy; Kelly Walkovich | Zendy; Preeti Jaggi | Zendy; Jennifer E Girotto | Zendy; April Yarbrough | Zendy; Edward M. Behrens | Zendy; Randy Q. Cron | Zendy; Hamid Bassiri | Zendy

Open Access

Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute Coronavirus Disease 2019 in Pediatric Patients

Author(s) -

Daniel E. Dulek,

Robert C. Fuhlbrigge,

Alison C. Tribble,

James A. Connelly,

Michele Loi,

Hassan El Chebib,

Shanmuganathan Chandrakasan,

W Otto,

Caroline Diorio,

Garrett Keim,

Kelly Walkovich,

Preeti Jaggi,

Jennifer E Girotto,

April Yarbrough,

Edward M. Behrens,

Randy Q. Cron,

Hamid Bassiri

Publication year - 2020

Publication title -

journal of the pediatric infectious diseases society

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.269

H-Index - 31

eISSN - 2048-7207

pISSN - 2048-7193

DOI - 10.1093/jpids/piaa098

Subject(s) - medicine , covid-19 , coronavirus , multidisciplinary approach , intensive care medicine , disease , pandemic , medline , virology , infectious disease (medical specialty) , outbreak , social science , sociology , political science , law

Immune-mediated lung injury and systemic hyperinflammation are characteristic of severe and critical coronavirus disease 2019 (COVID-19) in adults. Although the majority of severe acute respiratory syndrome coronavirus 2 infections in pediatric populations result in minimal or mild COVID-19 in the acute phase of infection, a small subset of children develop severe and even critical disease in this phase with concomitant inflammation that may benefit from immunomodulation. Therefore, guidance is needed regarding immunomodulatory therapies in the setting of acute pediatric COVID-19. This document does not provide guidance regarding the recently emergent multisystem inflammatory syndrome in children (MIS-C).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research